Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

418456

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Muscular Dystrophy
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to promote research into muscular dystrophy conditions.
	tabling member constituency	East Londonderry
	tabling member printed	Mr Gregory Campbell
	uin	9997
	answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The Department's National Institute for Health Research (NIHR) welcomes funding applications for research into any aspect of human health, including muscular dystrophies. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p><p> </p><p> </p><p>Research on novel approaches to treating neuromuscular disease including Duchenne muscular dystrophy is being carried out by the NIHR Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Trust and the University College London Institute of Child Health.</p><p> </p><p> </p><p> </p><p>The NIHR Health Technology Assessment programme is currently seeking to commission research on the effectiveness and cost-effectiveness of mechanical insufflation-exsufflation devices when compared to other methods of sputum clearance commonly used in children and young people with neuromuscular disease.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:27:44 answering member 4020 label Biography information for George Freeman
	tabling member	1409 label Biography information for Mr Gregory Campbell

418455

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Prostate Cancer
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when he expects the final results of the National Institute for Health Research's ProtecT trials for prostate cancer testing to be published; and if he will make a statement.
	tabling member constituency	East Londonderry
	tabling member printed	Mr Gregory Campbell
	uin	9996
	answer	answer is ministerial correction date of answer 16/09/2015 answer text <p>The ProtecT randomised controlled trial is evaluating the effectiveness, cost-effectiveness and acceptability of active monitoring, radical 3D conformal radiotherapy and radical prostatectomy in men with clinically localised prostate cancer, identified through population-based PSA (Prostate Specific Antigen) testing.</p><p> </p><p> </p><p> </p><p>There have already been over 100 published outputs from ProtecT and these are listed on the National Institute for Health Research (NIHR) website:</p><p> </p><p> </p><p> </p><p>www.nets.nihr.ac.uk/projects/hta/962099</p><p> </p><p> </p><p> </p><p>The researchers plan to publish the primary and most secondary analyses during 2016 at major relevant conferences and in peer-reviewed journals. The primary outcome to be evaluated is definite or probable prostate cancer specific mortality at a median of 10 years following randomisation. A monograph covering these findings is expected to be published in the NIHR Journals Library in July 2017. Findings from longer term follow-up will be published at a later stage.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 16/09/2015 15:17:51 answering member 4020 label Biography information for George Freeman
	tabling member	1409 label Biography information for Mr Gregory Campbell

418457

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ehlers-Danlos Syndrome
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what the average length of time is between the diagnosis of a patient with Ehlers-Danlos syndrome and referral for specialist treatment in (a) London and (b) Greater Manchester.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9989
	answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Information on patient outcomes of those diagnosed with Ehlers-Danlos Syndrome (EDS) in London and Greater Manchester is not held centrally by the Department. EDS falls within specialised services managed by NHS England.</p><p> </p><p> </p><p> </p><p>The UK Strategy for Rare Diseases sets out the Government’s on-going commitment to ensuring that patients with rare diseases, including EDS, have access to high quality services. The Strategy is discussed regularly with health bodies including NHS England. The national specialised service for atypical or complex cases aims to reduce times to diagnosis and reduce the number of hospital appointments required to achieve a specific diagnosis.</p><p> </p><p> </p><p> </p><p>Information about the average time from diagnosis to referral for specialist treatment is not available centrally. Patients suspected of having EDS may be assessed and diagnosed in a wide range of settings. These include United Kingdom regional clinical genetics clinics and various other secondary and tertiary speciality clinics.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9987 9988 question first answered 21/09/2015 10:00:17 answering member 4020 label Biography information for George Freeman
	tabling member	4140 label Biography information for Mr David Nuttall

418454

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ehlers-Danlos Syndrome
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent discussions his Department has had with health bodies on ensuring timely treatment for sufferers of Ehlers-Danlos syndrome.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9988
	answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Information on patient outcomes of those diagnosed with Ehlers-Danlos Syndrome (EDS) in London and Greater Manchester is not held centrally by the Department. EDS falls within specialised services managed by NHS England.</p><p> </p><p> </p><p> </p><p>The UK Strategy for Rare Diseases sets out the Government’s on-going commitment to ensuring that patients with rare diseases, including EDS, have access to high quality services. The Strategy is discussed regularly with health bodies including NHS England. The national specialised service for atypical or complex cases aims to reduce times to diagnosis and reduce the number of hospital appointments required to achieve a specific diagnosis.</p><p> </p><p> </p><p> </p><p>Information about the average time from diagnosis to referral for specialist treatment is not available centrally. Patients suspected of having EDS may be assessed and diagnosed in a wide range of settings. These include United Kingdom regional clinical genetics clinics and various other secondary and tertiary speciality clinics.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9987 9989 question first answered 21/09/2015 10:00:16 answering member 4020 label Biography information for George Freeman
	tabling member	4140 label Biography information for Mr David Nuttall

418461

	registered interest
	date	11/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Ehlers-Danlos Syndrome
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what recent assessment he has made of patient outcomes of those diagnosed with Ehlers-Danlos syndrome in (a) London and (b) Greater Manchester.
	tabling member constituency	Bury North
	tabling member printed	Mr David Nuttall
	uin	9987
	answer	answer is ministerial correction date of answer 21/09/2015 answer text <p>Information on patient outcomes of those diagnosed with Ehlers-Danlos Syndrome (EDS) in London and Greater Manchester is not held centrally by the Department. EDS falls within specialised services managed by NHS England.</p><p> </p><p> </p><p> </p><p>The UK Strategy for Rare Diseases sets out the Government’s on-going commitment to ensuring that patients with rare diseases, including EDS, have access to high quality services. The Strategy is discussed regularly with health bodies including NHS England. The national specialised service for atypical or complex cases aims to reduce times to diagnosis and reduce the number of hospital appointments required to achieve a specific diagnosis.</p><p> </p><p> </p><p> </p><p>Information about the average time from diagnosis to referral for specialist treatment is not available centrally. Patients suspected of having EDS may be assessed and diagnosed in a wide range of settings. These include United Kingdom regional clinical genetics clinics and various other secondary and tertiary speciality clinics.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9988 9989 question first answered 21/09/2015 10:00:13 answering member 4020 label Biography information for George Freeman
	tabling member	4140 label Biography information for Mr David Nuttall

418233

	registered interest
	date	10/09/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Morquio Syndrome: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, when he expects NICE to announce its decision on approving the Vimizim form of elosulfase alfa.
	tabling member constituency	Leeds North West
	tabling member printed	Greg Mulholland
	uin	9950
	answer	answer is ministerial correction date of answer 15/09/2015 answer text <p>The National Institute for Health and Care Excellence (NICE) published further draft guidance on 2 September 2015 which recommends elosulphase alfa (Vimizim) for the treatment of mucopolysaccharidosis (type IVA)/Morquio syndrome, subject to certain conditions. Interested parties now have until 23 September to comment on NICE’s draft recommendation.</p><p> </p><p> </p><p> </p><p>NICE now expects to publish its final guidance in January 2016.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 15/09/2015 11:36:47 answering member 4020 label Biography information for George Freeman
	tabling member	1540 label Biography information for Greg Mulholland

348260

	registered interest
	date	03/06/2015
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Batten Disease: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health, what steps he is taking to support research into the treatment of Batten Disease.
	tabling member constituency	Leeds North West
	tabling member printed	Greg Mulholland
	uin	995
	answer	answer is ministerial correction date of answer 12/06/2015 answer text <p>The National Institute for Health Research (NIHR) Clinical Research Network is hosting a commercial study to evaluate the safety and effectiveness of cerliponase alfa in patients with late-infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease. The NIHR also welcomes funding applications for research into any aspect of human health, including treatment of Batten disease. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 12/06/2015 10:53:53 answering member 4020 label Biography information for George Freeman
	tabling member	1540 label Biography information for Greg Mulholland

1149894

	registered interest
	date	16/10/2019
	answering body	Department for Transport
	answering dept id	27
	answering dept short name	Transport
	answering dept sort name	Transport
	hansard heading	Motorways: Accidents
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Transport, how many accidents there have been on Smart motorways as a result of a change in the use of lanes in each of the last three years.
	tabling member constituency	Hendon
	tabling member printed	Dr Matthew Offord
	uin	994
	answer	answer is ministerial correction date of answer 25/10/2019 answer text <p>It is not possible to provide data on the number of accidents on Smart motorways as a result of a change in use of lanes, as we cannot determine that as the cause.</p><p> </p><p>Data is collected on factors that contribute to how and why personal injury road accidents occur. However, it is not possible to attribute the cause of an accident to the presence or absence of Smart motorways operation.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 25/10/2019 13:45:30 answering member 4020 label Biography information for George Freeman
	tabling member	4006 label Biography information for Dr Matthew Offord

1466499

	registered interest
	date	26/05/2022
	answering body	Department for Business, Energy and Industrial Strategy
	answering dept id	201
	answering dept short name	Business, Energy and Industrial Strategy
	answering dept sort name	Business, Energy and Industrial Strategy
	hansard heading	New Businesses: Government Assistance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what support his Department is providing to establish business incubators.
	tabling member constituency	York Central
	tabling member printed	Rachael Maskell
	uin	9932
	answer	answer is ministerial correction date of answer 09/06/2022 answer text <p>The Levelling Up White Paper sets out how we will maximise the contribution of innovation to levelling up by building on existing and emerging strengths across the country. Innovation is a vital part of levelling up making businesses more productive, boosting wages and economic growth.</p><p> </p><p>Incubators and accelerators play a crucial role in helping entrepreneurs start and grow their business. This builds on several government programmes to support business including the Start Up Loans Company, Help to Grow: Management and Help to Grow: Digital – helping business to grow whilst levelling-up productivity across the UK.</p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 09/06/2022 08:37:30 answering member 4020 label Biography information for George Freeman
	tabling member	4471 label Biography information for Rachael Maskell

1149893

	registered interest
	date	16/10/2019
	answering body	Department for Transport
	answering dept id	27
	answering dept short name	Transport
	answering dept sort name	Transport
	hansard heading	Motorways
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Transport, what estimate he has made of the average time taken for Highways England to provide assistance to motorists on smart motorways after vehicular failure.
	tabling member constituency	Hendon
	tabling member printed	Dr Matthew Offord
	uin	993
	answer	answer is ministerial correction date of answer 25/10/2019 answer text <p>Highways England monitors the performance of its management of incidents across the Strategic Road Network.</p><p> </p><p>Highways England’s Traffic Officers provide assistance on the network to all motorists who require help.</p><p> </p><p>Using its recorded data, Highways England has summarised in the table below the average response times for Traffic Officers to arrive on scene at incidents which have been reported to, and are being managed, by its regional control centres.</p><p> </p><p>Highways England has used the same data parameters as set out in PQ answer 992.</p><p> </p><p>The amount of smart motorway increased during the assessed period, due to new schemes opening.</p><p> </p><p>This data provides Traffic Officer response times for breakdown incidents which are mapped to operational smart motorway locations.</p><p> </p><p>The average response time (in hh:mm:ss) for breakdown incidents between 2016 and 2018 is set out in the table below.</p><p> </p><table><tbody><tr><td><p><strong>Year</strong></p></td><td><p><strong>2016</strong></p></td><td><p><strong>2017</strong></p></td><td><p><strong>2018</strong></p></td></tr><tr><td><p>Total average response time</p></td><td><p>00:16:04</p></td><td><p>00:17:07</p></td><td><p>00:17:39</p></td></tr></tbody></table> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 25/10/2019 12:53:07 answering member 4020 label Biography information for George Freeman
	tabling member	4006 label Biography information for Dr Matthew Offord